arrow
A

Arianna Marinello

gustave roussy
H指数:9
被引数:312

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy of Alectinib for ALK-positive NSCLC According to Tumor Burden and Body Mass Index: a Pooled Analysis of the Randomized Phase III Trials ALEX and J-ALEX

根据肿瘤负荷和体重指数评估阿来替尼对ALK阳性NSCLC的疗效:ALEX和J-ALEX随机III期试验的合并分析

2026-06-050
OAAI
Clinical outcomes of compound EGFR mutations in non-small cell lung cancer: A national, retrospective, multicenter study.

非小细胞肺癌中复合EGFR突变的治疗效果:一项全国性、回顾性、多中心研究。

2025-06-250
PREAI
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors

AP1介导的EGFR表达重编程触发了RET易位肿瘤对BLU-667和LOXO-292的耐药性

2025-05-220
OA
Personalized Therapy in a Patient With EGFR- Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms

EGFR突变的NSCLC患者的个性化治疗发展序贯CCDC6-RET融合和BRAF V600E突变作为旁路耐药机制

2025-03-010
OA
Clinical utility of liquid biopsy in early stage lung cancer: A single institution experience
2024-03-220
PRE
Unraveling resistance and optimizing treatment through molecular profiling in patients with NSCLC and oncogenic fusions
2023-12-010
PRE
Clinical features of progression and outcomes with subsequent therapies in patients treated with RET-inhibitors
2023-12-010
PRE
Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients with advanced NSCLC and ALK, ROS1 or RET fusions
2023-04-040
PRE